Octasa 1600 mg modified-release tablets
4.1 Therapeutic indications
For the treatment of mild to moderate acute disease. For the maintenance of remission.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Treatment options for inflammatory bowel disease (IBD) are evolving as knowledge of the condition is increasing. In the future, physicians may be able to offer therapy tailored to individual patients. This Learning Zone describes the background behind such advances.
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).